Laboratorios Farmaceuticos Rovi, S.A. (LABFF)
USD 90.61
(0.0%)
USD 90.61
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 52.24 Million EUR | -12.11% |
| 2022 | 59.44 Million EUR | -10.94% |
| 2021 | 66.74 Million EUR | -2.45% |
| 2020 | 68.42 Million EUR | -5.11% |
| 2019 | 72.1 Million EUR | 334.65% |
| 2018 | 16.58 Million EUR | -38.63% |
| 2017 | 27.02 Million EUR | 29.77% |
| 2016 | 20.82 Million EUR | -36.17% |
| 2015 | 32.63 Million EUR | 1.87% |
| 2014 | 32.03 Million EUR | 41.87% |
| 2013 | 22.57 Million EUR | -22.51% |
| 2012 | 29.13 Million EUR | -29.36% |
| 2011 | 41.24 Million EUR | -4.28% |
| 2010 | 43.08 Million EUR | 72.8% |
| 2009 | 24.93 Million EUR | -13.05% |
| 2008 | 28.67 Million EUR | 29.31% |
| 2007 | 22.17 Million EUR | 82.29% |
| 2006 | 12.16 Million EUR | 0.0% |
| 2005 | - EUR | 0.0% |
| 2004 | - EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 59.62 Million EUR | 54.58% |
| 2024 Q2 | 98.14 Million EUR | -100.0% |
| 2023 Q4 | 52.24 Million EUR | 0.32% |
| 2023 FY | 52.24 Million EUR | -12.11% |
| 2023 Q1 | 56.87 Million EUR | -4.31% |
| 2023 Q2 | 54.54 Million EUR | -4.11% |
| 2023 Q3 | 52.07 Million EUR | -4.52% |
| 2022 Q1 | 66.06 Million EUR | -1.02% |
| 2022 FY | 59.44 Million EUR | -10.94% |
| 2022 Q2 | 66.37 Million EUR | 0.47% |
| 2022 Q4 | 59.44 Million EUR | -11.03% |
| 2022 Q3 | 66.8 Million EUR | 0.65% |
| 2021 Q1 | 67.38 Million EUR | -1.52% |
| 2021 Q4 | 66.74 Million EUR | 0.1% |
| 2021 FY | 66.74 Million EUR | -2.45% |
| 2021 Q2 | 67.24 Million EUR | -0.2% |
| 2021 Q3 | 66.67 Million EUR | -0.85% |
| 2020 FY | 68.42 Million EUR | -5.11% |
| 2020 Q4 | 68.42 Million EUR | -0.69% |
| 2020 Q3 | 68.89 Million EUR | -0.99% |
| 2020 Q2 | 69.58 Million EUR | -2.29% |
| 2020 Q1 | 71.21 Million EUR | -1.23% |
| 2019 Q4 | 72.1 Million EUR | 115.47% |
| 2019 Q1 | 33.3 Million EUR | 100.74% |
| 2019 FY | 72.1 Million EUR | 334.65% |
| 2019 Q2 | 34.45 Million EUR | 3.48% |
| 2019 Q3 | 33.46 Million EUR | -2.89% |
| 2018 FY | 16.58 Million EUR | -38.63% |
| 2018 Q3 | 20.64 Million EUR | 6.45% |
| 2018 Q2 | 19.38 Million EUR | -13.0% |
| 2018 Q1 | 22.28 Million EUR | -17.55% |
| 2018 Q4 | 16.58 Million EUR | -19.63% |
| 2017 Q4 | 27.02 Million EUR | -17.6% |
| 2017 FY | 27.02 Million EUR | 29.77% |
| 2017 Q3 | 32.8 Million EUR | -9.17% |
| 2017 Q2 | 36.11 Million EUR | -5.71% |
| 2017 Q1 | 38.29 Million EUR | 83.88% |
| 2016 Q1 | 29.96 Million EUR | -8.18% |
| 2016 Q2 | 27.05 Million EUR | -9.72% |
| 2016 Q3 | 24.27 Million EUR | -10.26% |
| 2016 Q4 | 20.82 Million EUR | -14.2% |
| 2016 FY | 20.82 Million EUR | -36.17% |
| 2015 Q4 | 32.63 Million EUR | -9.12% |
| 2015 Q2 | 29.19 Million EUR | -5.8% |
| 2015 Q3 | 35.9 Million EUR | 22.99% |
| 2015 Q1 | 30.99 Million EUR | -3.25% |
| 2015 FY | 32.63 Million EUR | 1.87% |
| 2014 Q3 | 32.88 Million EUR | 57.13% |
| 2014 Q2 | 20.92 Million EUR | -2.71% |
| 2014 Q4 | 32.03 Million EUR | -2.59% |
| 2014 FY | 32.03 Million EUR | 41.87% |
| 2014 Q1 | 21.51 Million EUR | -4.73% |
| 2013 Q4 | 22.57 Million EUR | -1.41% |
| 2013 Q3 | 22.9 Million EUR | -3.15% |
| 2013 Q2 | 23.64 Million EUR | -17.74% |
| 2013 Q1 | 28.74 Million EUR | -1.32% |
| 2013 FY | 22.57 Million EUR | -22.51% |
| 2012 Q1 | 35.81 Million EUR | -13.18% |
| 2012 Q4 | 29.13 Million EUR | -2.02% |
| 2012 Q3 | 29.73 Million EUR | 1571.44% |
| 2012 FY | 29.13 Million EUR | -29.36% |
| 2012 Q2 | 1.77 Million EUR | -95.03% |
| 2011 Q3 | 43.3 Million EUR | -0.95% |
| 2011 FY | 41.24 Million EUR | -4.28% |
| 2011 Q4 | 41.24 Million EUR | -4.75% |
| 2011 Q2 | 43.71 Million EUR | -3.76% |
| 2011 Q1 | 45.42 Million EUR | 5.43% |
| 2010 FY | 43.08 Million EUR | 72.8% |
| 2010 Q4 | 43.08 Million EUR | 0.0% |
| 2009 FY | 24.93 Million EUR | -13.05% |
| 2008 FY | 28.67 Million EUR | 29.31% |
| 2007 FY | 22.17 Million EUR | 82.29% |
| 2006 FY | 12.16 Million EUR | 0.0% |
| 2005 FY | - EUR | 0.0% |
| 2004 FY | - EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | - USD | -Infinity% |
| SQZ Biotechnologies Company | 20.9 Million USD | -149.854% |
| Evofem Biosciences, Inc. | 8000.00 USD | -652925.0% |
| Santhera Pharmaceuticals Holding AG | 1.75 Million USD | -2875.94% |
| Mesoblast Limited | 100.29 Million USD | 47.912% |
| Propanc Biopharma, Inc. | 58.64 Thousand USD | -88986.32% |
| Genus plc | 228.2 Million USD | 77.107% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | - USD | -Infinity% |
| Marizyme, Inc. | 667.12 Thousand USD | -7730.869% |
| ContraFect Corporation | 2.21 Million USD | -2263.891% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.4 Million USD | -3623.767% |
| Intellipharmaceutics International Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 5.42 Million USD | -862.724% |
| MultiCell Technologies, Inc. | 36.43 USD | -143403688.087% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 55.61 Million USD | 6.06% |
| EV Biologics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 2.22 Million USD | -2246.9% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -4152.984% |
| Biomind Labs Inc. | - USD | -Infinity% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 166.1 Million USD | 68.549% |
| Oncotelic Therapeutics, Inc. | 1.89 Million USD | -2651.798% |
| Skye Bioscience, Inc. | 171.23 Thousand USD | -30409.841% |
| Therapeutic Solutions International, Inc. | 5512.00 USD | -947686.647% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | - USD | -Infinity% |
| IMV Inc. | 27.39 Million USD | -90.674% |
| Acro Biomedical Co., Ltd. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | 322 Thousand USD | -16124.224% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 11.23 Billion USD | 99.535% |
| Halberd Corporation | 150 Thousand USD | -34728.0% |
| Enzolytics Inc. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 300 Thousand USD | -17314.0% |
| Nuo Therapeutics, Inc. | 164.2 Thousand USD | -31715.109% |
| argenx SE | 15.35 Million USD | -240.25% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 20.31 Million USD | -157.198% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 4456.00 USD | -1172296.768% |
| Genscript Biotech Corporation | 287.12 Million USD | 81.805% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 126.3 Thousand USD | -41262.765% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -22684.148% |
| American Oriental Bioengineering, Inc. | 554.59 Thousand USD | -9319.932% |
| Provectus Biopharmaceuticals, Inc. | 25.29 Thousand USD | -206398.281% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 8.26 Million USD | -532.164% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 265.63 Thousand USD | -19566.836% |
| ONE Bio Corp. | 592.19 Thousand USD | -8721.712% |
| Reve Technologies, Inc. | 1064.00 USD | -4909862.406% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -34817.855% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -34817.855% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 229.69 Thousand USD | -22644.47% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| CytoDyn Inc. | 141 Thousand USD | -36951.064% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 80 Thousand USD | -65202.5% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -568.06% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 369.04 Thousand USD | -14055.844% |
| International Stem Cell Corporation | 445 Thousand USD | -11639.775% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.15 Million USD | -541.006% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | 457 Thousand USD | -11331.51% |
| Neutra Corp. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 1.16 Million USD | -4399.742% |
| PureTech Health plc | 18.25 Million USD | -186.258% |
| Coeptis Therapeutics, Inc. | 150 Thousand USD | -34728.0% |
| IXICO plc | 275 Thousand USD | -18897.091% |
| IntelGenx Technologies Corp. | 11.83 Million USD | -341.27% |
| Gelesis Holdings, Inc. | 26.3 Million USD | -98.571% |
| CSL Limited | 11.23 Billion USD | 99.535% |
| Cellectis S.A. | 36.21 Million USD | -44.271% |